-
Je něco špatně v tomto záznamu ?
Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease
TM. Gorter, M. Obokata, YNV. Reddy, V. Melenovsky, BA. Borlaug,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
R01 HL128526
NIH HHS - United States
R01 HL 126638
NIH HHS - United States
U01 HL125205
NIH HHS - United States
U10 HL110262
NIH HHS - United States
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
PubMed
29947750
DOI
10.1093/eurheartj/ehy331
Knihovny.cz E-zdroje
- MeSH
- arteria pulmonalis * MeSH
- lidé MeSH
- nemoci cév etiologie MeSH
- senioři MeSH
- srdeční selhání komplikace patofyziologie MeSH
- tepový objem * MeSH
- venae pulmonales * MeSH
- zátěžový test * MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
Aims: Pulmonary hypertension (PH) and pulmonary vascular disease (PVD) are common and associated with adverse outcomes in heart failure with preserved ejection fraction (HFpEF). Little is known about the impact of PVD on the pathophysiology of exercise intolerance. Methods and results: Heart failure with preserved ejection fraction patients (n = 161) with elevated pulmonary capillary wedge pressure (≥15 mmHg) at rest were classified into three groups: non-PH-HFpEF (n = 21); PH but no PVD (isolated post-capillary PH, IpcPH; n = 95); and PH with PVD (combined post- and pre-capillary PH, CpcPH; n = 45). At rest, CpcPH-HFpEF patients had more right ventricular (RV) dysfunction and lower pulmonary arterial (PA) compliance compared to all other groups. While right atrial pressure (RAP) and left ventricular transmural pressure (LVTMP) were similar in HFpEF with and without PH or PVD at rest, CpcPH-HFpEF patients demonstrated greater increase in RAP, enhanced ventricular interdependence, and paradoxical reduction in LVTMP during exercise, differing from all other groups (P < 0.05). Lower PA compliance was correlated with greater increase in RAP with exercise. During exercise, CpcPH-HFpEF patients displayed an inability to enhance cardiac output, reduction in forward stroke volume, and blunted augmentation in RV systolic performance, changes that were coupled with marked limitation in aerobic capacity. Conclusion: Heart failure with preserved ejection fraction patients with PVD demonstrate unique haemodynamic limitations during exercise that constrain aerobic capacity, including impaired recruitment of LV preload due to excessive right heart congestion and blunted RV systolic reserve. Interventions targeted to this distinct pathophysiology require testing in patients with HFpEF and PVD.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045396
- 003
- CZ-PrNML
- 005
- 20200113082141.0
- 007
- ta
- 008
- 200109s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/eurheartj/ehy331 $2 doi
- 035 __
- $a (PubMed)29947750
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Gorter, Thomas M $u Department of Cardiovascular Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, USA. Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, RB Groningen, The Netherlands.
- 245 10
- $a Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease / $c TM. Gorter, M. Obokata, YNV. Reddy, V. Melenovsky, BA. Borlaug,
- 520 9_
- $a Aims: Pulmonary hypertension (PH) and pulmonary vascular disease (PVD) are common and associated with adverse outcomes in heart failure with preserved ejection fraction (HFpEF). Little is known about the impact of PVD on the pathophysiology of exercise intolerance. Methods and results: Heart failure with preserved ejection fraction patients (n = 161) with elevated pulmonary capillary wedge pressure (≥15 mmHg) at rest were classified into three groups: non-PH-HFpEF (n = 21); PH but no PVD (isolated post-capillary PH, IpcPH; n = 95); and PH with PVD (combined post- and pre-capillary PH, CpcPH; n = 45). At rest, CpcPH-HFpEF patients had more right ventricular (RV) dysfunction and lower pulmonary arterial (PA) compliance compared to all other groups. While right atrial pressure (RAP) and left ventricular transmural pressure (LVTMP) were similar in HFpEF with and without PH or PVD at rest, CpcPH-HFpEF patients demonstrated greater increase in RAP, enhanced ventricular interdependence, and paradoxical reduction in LVTMP during exercise, differing from all other groups (P < 0.05). Lower PA compliance was correlated with greater increase in RAP with exercise. During exercise, CpcPH-HFpEF patients displayed an inability to enhance cardiac output, reduction in forward stroke volume, and blunted augmentation in RV systolic performance, changes that were coupled with marked limitation in aerobic capacity. Conclusion: Heart failure with preserved ejection fraction patients with PVD demonstrate unique haemodynamic limitations during exercise that constrain aerobic capacity, including impaired recruitment of LV preload due to excessive right heart congestion and blunted RV systolic reserve. Interventions targeted to this distinct pathophysiology require testing in patients with HFpEF and PVD.
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a zátěžový test $7 D005080
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a srdeční selhání $x komplikace $x patofyziologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a arteria pulmonalis $7 D011651
- 650 12
- $a venae pulmonales $7 D011667
- 650 12
- $a tepový objem $7 D013318
- 650 _2
- $a nemoci cév $x etiologie $7 D014652
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Obokata, Masaru $u Department of Cardiovascular Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, USA.
- 700 1_
- $a Reddy, Yogesh N V $u Department of Cardiovascular Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, USA.
- 700 1_
- $a Melenovsky, Vojtech $u Department of Cardiovascular Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, USA. Department of Cardiology, Institute of Clinical and Experimental Medicine - IKEM, Videnska 1958/9, Prague, Czech Republic.
- 700 1_
- $a Borlaug, Barry A $u Department of Cardiovascular Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, USA.
- 773 0_
- $w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 39, č. 30 (2018), s. 2825-2835
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29947750 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113082513 $b ABA008
- 999 __
- $a ok $b bmc $g 1483665 $s 1084069
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 39 $c 30 $d 2825-2835 $e 20180807 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
- GRA __
- $a R01 HL128526 $p NIH HHS $2 United States
- GRA __
- $a R01 HL 126638 $p NIH HHS $2 United States
- GRA __
- $a U01 HL125205 $p NIH HHS $2 United States
- GRA __
- $a U10 HL110262 $p NIH HHS $2 United States
- LZP __
- $a Pubmed-20200109